Skip to main content

Table 1 Patient demographics, and disease and concomitant treatment characteristics

From: The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia

Characteristic Total evaluable patients
(N = 224)
Age, years, mean (SD) 45.3 (13.45)
Males, n (%) 160 (71.4)
Family status, single, n (%); n = 222 144 (64.9)
Living arrangement, n (%)
 Alone 65 (29.0)
 With family (parents/siblings) 97 (43.3)
 With partner/children 42 (18.8)
 Other 20 (8.8)
In education/employment, yes, n (%) 54 (24.3)a
 Student 7 (3.2)
 Employed (paid, voluntary, self-employed) 46 (20.8)
Country, n (%)
 Belgium 4 (1.8)
 France 63 (28.1)
 Germany 6 (2.7)
 Hungary 23 (10.3)
 Italy 37 (16.5)
 Spain 84 (37.5)
 United Kingdom 7 (3.1)
Patients receiving other non-pharmacological treatments or care currently, yes (%); n = 218 96 (44.0)
Years living with schizophrenia diagnosis, mean (SD); n = 214 12.0 (10.15)
Years taking antipsychotic medication, mean (SD); n = 211 12.1 (9.69)
EQ-5D-5L VAS, mean (SD); n = 190b 70.8 (19.60)
CGI-Severity score, mean (SD); n = 221 3.7 (0.99)
CGI-Severity categories,c n (%); n = 221
 Normal, not at all ill 5 (2.3)
 Borderline mentally ill 17 (7.7)
 Mildly ill 60 (27.1)
 Moderately ill 101 (45.7)
 Markedly ill 31 (14.0)
 Severely ill 7 (3.2)
PANSS item G12 lack of judgement and insight, mean (SD); n = 212 3.2 (1.30)
PANSS item G12 lack of judgement and insight categories, n (%);d n = 212
 Absent 19 (9.0)
 Minimal 38 (17.9)
 Mild 77 (36.3)
 Moderate 44 (20.8)
 Moderate severe 20 (9.4)
 Severe 13 (6.1)
 Extreme 1 (0.5)
Current psychiatric comorbidities, yes, n (%);e n = 222 59 (26.6)
Other concomitant psychotropic treatments currently prescribed in addition to PP3M, yes, n (%);f n = 221 139 (62.9)
 Oral antipsychotic 78 (35.3)
 Anxiolytic/hypnotic 77 (34.8)
 Anticholinergic 18 (8.1)
 Antidepressant 47 (21.3)
 Mood stabiliser 25 (11.3)
  1. aOne patient was confirmed to be either in employment or education; however, this was not further specified; bPatients recorded their own assessment of their overall health status on a scale of 0 (worst health) to 100 (best health) [15]; cSeverity of patient’s psychotic condition at a particular time on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients) [16]; dA scale of 1 (absent) to 7 (extreme) [17]; ePatients may have had more than one comorbidity; fPatients may have been taking more than one medication. CGI, Clinical Global Impression; EQ-5D-5L, EuroQoL-5D; PANSS, Positive and Negative Syndrome Scale; PP3M, paliperidone palmitate 3-monthly; SD, standard deviation; VAS, visual analogue scale